Biotop-report 2011

7

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

on myocardial, vascular and metabolic mechanisms of cardio-

vascular diseases with systematic consideration of lifestyle, age, 

gender and ethnicity for more effective cardiovascular prevention. 

Interventional and preventive cardiologists will work together 

with surgeons, basic scientists and public health experts in an 

interdisciplinary institute. Extramural partners include industrial, 

healthcare and insurance companies. The DZHK will be financed 

by 90 % from central governmental funds and by 10 % by regional 

governmental funds.

News

 

November 2010

 

p

The Leibniz Institute for  Molecular 

Pharmacology (FMP) in Berlin 

receives 3.7 million euros from the 

European Union for a three-year 

preparation phase of the EU-OPEN 

SCREEN project.

 

p

Sofya Kovalevskaya Prize 2010 win-

ners in the field of biotechnology, 

Dr. Dmitry Volodkin and Dr. Isabel 

Bäurle establish research groups at 

the Potsdam University.

 

p

Prof. Ulrike Stein of the MDC receives 

Monika-Kutzner Prize for Cancer 

Research 

December 2010

 

p

Topping-out ceremony at the Bio-

medizintechnikum II at the Center 

for Biomaterials in Teltow 

January 2011

 

p

Prof. Andreas Radbruch of the 

 German Rheumatism Research 

 Center Berlin (DRFZ) receives 

Advanced Grant of the  European 

Research Council (ERC) in the 

amount of 2.5 million €.

 

p

Prof. Klaus Rajewsky receives 

Advanced Grant of the Euro-

pean Research Council (ERC) in the 

amount of 2.5 million € and estab-

lishes working group at the MDC 

February 2011

 

p

ESGI project (the European Sequenc-

ing and Genotyping Infrastructure), 

coordinated by the Max-Planck-

Institute for Molecular Genetics, 

starts.

March 2011

 

p

Charité-scientist Andrea Ode of the 

Julius Wolff Institute wins BIONNALE 

Speed Lecture Award.

 

p

Prof. Oliver Daumke from the Max 

Delbrück Center for Molecular 

Medicine (MDC) Berlin-Buch receives 

“Bayer Early Excellence in Science 

Award 2010” for biology. 

April 2011

 

p

Berlin research consortium becomes 

part of the German Center for 

 Cardiovascular Research (DZHK)

 

p

Dr. Daniel Toben of Charité receives 

Raisz-Drezner-Award of the Ameri-

can Society of Bone and Mineral 

Research (ASBMR)

 

p

BioTOP and BCRT publish technology 

report on Regenerative Medicine in 

Berlin-Brandenburg

 

p

Prof. Jan Schwab of the Depart-

ment of Neurology at the Charité 

and the Berlin-Brandenburg Center 

for Regenerative Therapies (BCRT) 

received the Novartis Award for 

therapy relevant pharmacological 

research.

Excellent Conditions for Research

»

When I felt the desire to return to Germany after an 

extended stay in the USA, I looked for programmes 

which would permit me to build up an independent work-

ing group at a German research institute. In particular the 

Emmy Noether Programme of the German Research Founda-

tion (DFG) and the Kovalevskaja Programme of the Alexander 

von Humboldt Foundation, which is funded by the German 

Federal  Ministry  of  Education  and  Research,  finance  proj-

ects of this kind. I applied successfully with the support of 

Prof. Peter Hegemann and Humboldt-Universität as the host 

institution and have now been in Berlin since summer 2010. 

The city provides an outstanding environment for my field of 

research: optogenetics.

Prof. Dr. Andreas Möglich

in the Institute of Biology at  Humboldt-Universität zu Berlin will conduct 

research in the German capital for the next five years as a winner of the Sofja 

Kovalevskaja Award.

Federal Funding (BMBF) for R&D projects

… in research institutions

 

per capita funding (euro)

Berlin 

61,78

Mecklenburg-Vorpommern 

38,84

Sachsen-Anhalt 

30,15

Baden-Württemberg 

27,71

Hamburg 

26,37

Sachsen-Anhalt 

25,33

Thüringen 

22,7

Schleswig-Holstein 

22,66

Saarland 

20,06

Bremen 

18,21 

… in the life sciences at German universities 

 

projects 

mio euro

Charité - Universitätmedizin Berlin 

168 92

University Freiburg 

117 57,4

University Heidelberg 

141 48,6

University Kiel 

65 43,7

LMU München 

132 43,6

University Leipzig 

65 43,2

Figures for 2005-2009, source: ConsulTech GmbH, 2010 

---

8

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

A unique European infrastructure for 

sequencing and genotyping 

The Max Planck Society is also extremely active in Berlin-Branden-

burg. Its Max Planck Institutes for Molecular Genetics, Infection 

Biology and Molecular Plant Physiology belong to the world’s 

leading facilities in their respective fields. 

In February 2011, a consortium of leading European research 

establishments began to build a European infrastructure for 

genome sequencing and genotyping. The project ESGI (European 

Sequencing and Genotyping Infrastructure) is being coordinated 

by the German Max Planck Institute for Molecular Genetics and 

funded by the European Commission under the auspices of the 

Seventh Framework Programme for Research and Technologi-

cal Development. The participating institutions come from Aus-

tria, France, Germany, Spain, Sweden and Britain. The ESGI is to 

enhance Europe’s position as a leading force in global genetics, 

genome research and molecular biology. The ESGI infrastructure 

will combine the efforts of leading European institutions in the 

fields  of  biology  and  bioinformatics  to  ensure  that  the  broader 

research community can access genetic data and use the newest 

analytical tools. The aim is to permit scientists from all disci-

plines to use state-of-the-art technologies to decode complex 

gene functions at economic cost. Following the establishment of 

the infrastructure scientists will be able to sequence a genome for 

only app. 1,000 Euros.

Aaron Motsoaledi

Minister of Health of South Africa, at the World Health Summit 2010

Detlev Ganten

President of the World Health Summit

Winner of the BIONNALE Speed Lecture Award 2011: Andrea Ode from the 

Julius Wolff Institute for  Biomechanics and Musculoskeletal Regeneration, 

with Dr. Kai Bindseil, director of BioTOP

Charité as an Entrepreneur 

»

The motto of the Charité is: “We bring the best medicine 

to the hospital bed”. Continuous advances in science 

and technology offer many opportunities for fundamen-

tal changes in patient therapy. At the Charité, where doc-

tors and scientists conduct research at the most advanced 

international level, we want to accelerate the introduction 

of the results of this research into patient care. This is why 

we have set ourselves the strategic goal of becoming the 

leading partner of the medical and pharmaceutical industry 

in  Germany.  With  cooperation  partners  like  Sanofi-Aventis 

or Novartis we are already implementing new concepts for 

cooperation between research establishments and industry. 

This new culture of exchange is in our mutual interest. Our 

partnerships will speed up joint product development based 

on our strong university hospital research.

Prof. Karl Max Einhäupl

Chairman of the Executive Board

Charité - Universitätsmedizin Berlin

---